Lilly Gets FDA Approval For New Oral Tablets For Migraine
Zacks Investment Research | Oct 13, 2019 10:14PM ET
Eli Lilly & Company (NYSE:LLY) announced that the FDA has approved lasmiditan for the treatment of acute migraine headaches, with or without aura, in adults. Lasmiditan, an oral 5-HT1F agonist, is the first and only FDA-approved medicine in this class of migraine drugs. Lasmiditan will be marketed by the trade name of Reyvow and will be available in oral doses of 50 mg, 100 mg, and 200 mg, once launched.
The new drug application for Reyvow was based on data from two phase III studies, SAMURAI and SPARTAN. Both the studies met the efficacy endpoints. Data from the studies showed that treatment with Reyvow led to pain freedom and freedom from most bothersome symptoms of migraine at two hours after administration of Reyvow compared to placebo.
Please note that lasmiditan was added to Lilly’s portfolio with the 2017 acquisition of CoLucid Pharmaceuticals.
Year to date, Lilly’s shares have declined 6.3% compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.